# 211At-MABG in Adults With Advanced Neuroendocrine Cancers

> **NCT07661420** · PHASE1 · NOT_YET_RECRUITING · sponsor: **University of Pennsylvania** · enrollment: 16 (estimated)

## Conditions studied

- Pheochromocytoma
- Paraganglioma
- Neuroendocrine Tumors
- Medullary Thyroid Cancer
- Bronchial Carcinoid
- Gastroenteropancreatic Neuroendocrine Neoplasm

## Interventions

- **DRUG:** 1 MBq/k of 211At-MABG Fractionated
- **DRUG:** 2 MBq/k1 of 211At-MABG Fractionated
- **DRUG:** 4 MBq/k of 211At-MABG Fractionated

## Key facts

- **NCT ID:** NCT07661420
- **Lead sponsor:** University of Pennsylvania
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-12-01
- **Primary completion:** 2029-08-01
- **Final completion:** 2032-08-01
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2026-10-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07661420

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07661420, "211At-MABG in Adults With Advanced Neuroendocrine Cancers". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07661420. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*